Analyst Price Target is $43.40
▲ +44.09% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Veracyte in the last 3 months. The average price target is $43.40, with a high forecast of $51.00 and a low forecast of $28.00. The average price target represents a 44.09% upside from the last price of $30.12.
Current Consensus is
Moderate Buy
The current consensus among 10 contributing investment analysts is to moderate buy stock in Veracyte. This Moderate Buy consensus rating has held steady for over two years.
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Read More